

Science

[\(https://www.thehindubusinessline.com/news/science/\)](https://www.thehindubusinessline.com/news/science/)

PHARMA


Dr Reddy's Labs announces commercial launch of 2-DG

Our Bureau (<https://www.thehindubusinessline.com/profile/author/Our-Bureau-15447/>) Hyderabad | Updated on June 28, 2021

[f](#) [t](#) [in](#) [📧](#) (mailto:?)

subject=Dr%20Reddy%E2%80%99s%20Labs%20announces%20commercial%20launc

21



MRP of each sachet fixed at ₹990; subsidised rate offered to government institutions

Dr Reddy's Laboratories has announced the commercial launch of 2-deoxy-D-glucose (2-DG), a drug for moderate to severe Covid-19 patients administered as an adjunct therapy to the existing standard care.

The emergency use approval for anti-Covid-19 therapeutic application of the drug was granted on May 1, 2021.

 **Subscriber Exclusive**



Economy (<https://www.thehindubusinessline.com/Economy/>)

FM INTERVIEW

No tax increase to meet Covid spend: Nirmala Sitharaman

(<https://www.thehindubusinessline.com/economy/no-tax-increase-to-meet-...>)

(<https://www.thehindubusinessline.com/economy/no-tax-increase-to-meet-covid-spend-finmin/article35066297.ece>)

Also read: Dr Reddy's launches Icosapent Ethyl capsules in US
(<https://www.thehindubusinessline.com/companies/dr-reddys-launches-icosapent-ethyl-capsules-in-us/article34898946.ece>)

Dr Reddy's will supply to major government as well as private hospitals across India. In the initial weeks, the company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the rest of India.

2-DG manufactured by Dr Reddy's has a purity of 99.5 per cent and is being sold commercially under the brand name 2-DG. The maximum retail price (MRP) of each sachet has been fixed at ₹990, with a subsidised rate offered to government institutions.

2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's Labs.

The oral drug can be administered only upon prescription and under the supervision of a qualified physician to hospitalised patients.

Dr G Satheesh Reddy, Secretary - Department of Defence (R&D) and Chairman, DRDO, in a statement said: "We are pleased to have worked closely with our long-term industry partner Dr Reddy's Laboratories, Hyderabad, for testing 2-DG as therapeutic application in treatment of Covid-19 patients. DRDO has been contributing in the fight against Covid-19 pandemic with its spin-off technologies."

Satish Reddy, Chairman, Dr Reddy's, said: "2-DG is yet another addition to our Covid-19 portfolio that already covers the full spectrum of mild to moderate and severe conditions and includes a vaccine. We are extremely pleased to have partnered with DRDO in our collective fight against the Covid-19 pandemic."

Published on June 28, 2021

Follow us on Telegram (<https://t.me/HinduBusinessLine>), Facebook (<https://www.facebook.com/TheHinduBusinessLine>), Twitter, (<https://twitter.com/businessline>) Instagram (https://www.instagram.com/hindu_businessline/), YouTube (<https://www.youtube.com/user/HinduBusinessLine>) and LinkedIn (<https://www.linkedin.com/company/business-line-aka-the-hindu-business-line?trk=biz-companies-cym>). You can also download our Android App (<https://play.google.com/store/apps/details?id=com.mobstac.thehindubusinessline>) or IOS App. (<https://apps.apple.com/in/app/business-line-for-iphone/id855182339>)

Get more of your favourite news delivered to your inbox

SUBSCRIBE